TITLE

Improved survival in HIV-infected African-Americans with ESRD

AUTHOR(S)
Macrae, J.; Friedman, A. L.; Eggers, P.; Friedman, E. A.
PUB. DATE
August 2005
SOURCE
Clinical Nephrology;2005, Vol. 64 Issue 2, p124
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aims To determine if there has been improvement in survival of HIV-infected patients with end-stage renal failure sub sequent to widespread use of highly active antiretroviral therapy. Methods: The United States Renal Data System is a national data system funded by the National Institute of Diabetes and Digestive and Kidney Disease with the Centers for Medicare and Medicaid. Using the United States Renal Data System Standard Analysis Files, we analyzed all African-American end-stage renal failure patients in the United States from 1990 - 2001. We compared survival rates for patients with HIV disease, sickle cell anemia, diabetes, and all other diagnoses for the time periods 1990- 1994 and 1995-2001. The main outcome measure was one- and five-year survival in each cohort. Results: One-year survival of African-American patients with end-stage renal disease and HIV increased from 46.6% during 1990 - 1994 to 65.1% during 1995 - 2001 (odds ratio 2.139). One-year survival decreased in the sickle cell group (odds ratio 0.5 95) and decreased slightly in the diabetic group (odds ratio 0.927) and all others (odds ratio 0.94 1). Five-year survival in the HIV group increased from 13.3% in 1990 - 1995 to 30.4% in 1995 - 2001 (odds ratio 2.847). There was no corresponding increase in survival for the sickle cell group (odds ratio 0.987), the diabetic group (odds ratio 1.06), or all others (odds ratio 1.137). Conclusions: We conclude that survival in African-American end-stage renal disease patients and HIV infection has substantially improved subsequent to introduction of highly active antiretroviral therapy. Our data support aggressive multi-drug treatment of end-stage renal failure patients with HIV infection.
ACCESSION #
18320953

 

Related Articles

  • Adverse Reaction Research.  // Reactions Weekly;7/21/2007, Issue 1161, p2 

    The article discusses research being done on indinavir and tenofovir disoproxil fumarate. It references a study by A. Mocroft et al published in a May 2007 issue of "AIDS." The study demonstrated the link between indinavir and tenofovir disoproxil fumarate and increased risk of chronic renal...

  • Patient Adherence To HAART Regimens: Challenges For Physician Assistants And Health Care Providers. Day, Marvin // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p42 

    Patients often adhere incompletely and inadequately to highly active antiretroviral therapy (HAART) regimens used in the treatment of HIV infection. This permits the emergence of HIV variants that are resistant to current treatment. The physician assistant often assumes the responsibility for...

  • Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States. Brogan, Anita J.; Mrus, Joseph; Hill, Andrew; Sawyer, Anthony W.; Smets, Erik // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p133 

    Purpose: A comprehensive study comparing the costs and efficacies of darunavir/ritonavir 800/100 mg qd and the other ritonavir-boosted (/r) protease inhibitors (PIs) recommended for treatment-naïve individuals with HIV-1 infection would help health care decision makers identify the value of...

  • HIV associated nephropathy: a treatable condition. Brook, M Gary; Miller, Robert F; Brook, M G; Miller, R F // Sexually Transmitted Infections;Apr2001, Vol. 77 Issue 2, p97 

    Objectives: To describe current knowledge on the aetiology, pathology, diagnosis, and treatment of HIV associated nephropathy.Methods: A Medline search was performed using the key words "HIV," "nephropathy," "renal," and "kidney." A further search was performed for each...

  • Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane // HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163 

    Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks...

  • Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens. Pan, Angelo; Testa, Sophie; Roldan, Eugenia Quiros; Tinelli, Carmine; Bodini, Umberto; Cadeo, Barbara; Carnevale, Giuseppe; Martinelli, Ida; Maserati, Renato; Morstabilini, Pietro; Seminari, Elena; Signorini, Liana; Carosi, Giampiero // Current HIV Research;Jan2008, Vol. 6 Issue 1, p70 

    HIV infected patients treated with highly active antiretroviral therapy (HAART) may be at increased risk of cardiovascular events, particularly if based upon the use of protease inhibitors (PI). We investigated the haemostatic markers of cardiovascular risk in 115 HIV infected subjects, divided...

  • Living in rural New England amplifies the risk of depression in patients with HIV. Sheth, Siddharth H.; Jensen, Paul T.; Lahey, Timothy // BMC Infectious Diseases;2009, Vol. 9 Issue 1, Special section p1 

    Background: The importance of depression as a complication of HIV infection is increasingly understood, and people living in rural areas are at increased risk for depression. However, it is not known whether living in rural areas amplifies the risk of depression in patients with HIV. Methods: We...

  • Reduced Risk of Tuberculosis among Brazilian Patients with Advanced Human Immunodeficiency Virus Infection Treated with Highly Active Antiretroviral Therapy. Santoro-Lopes, Guilherme; De Pinho, Ana Maria Felix; Harrison, Lee H.; Schechter, Mauro // Clinical Infectious Diseases;2/15/2002, Vol. 34 Issue 4, p543 

    Presents information on a study which assessed the effect of combination antiretroviral therapy on the risk of tuberculosis among patients with HIV infection in Brazil. Use of highly active antiretroviral therapy for the treatment of HIV infection; Transmission of mycobacterium tuberculosis in...

  • Oral lesions among HIV seropositive individuals in an era of generic HAART: markers of HAART efficacy? Vasudevan, Janani; Sivasankar, Vaishnavi; Rao, Umadevi K.; Kumarasamy, Nagalingeswaran; Ranganathan, Kannan // BMC Infectious Diseases;2012 Supplement, Vol. 12 Issue Supplment 1, p1 

    The article presents a study on the prevalence of oral lesions among HIV seropositive individuals in India. The authors investigate the prevalence of oral lesions among HIV patients on Highly Active Antiretroviral Therapy (HAART). They state that patients under HAART have fewer orals lesions,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics